Listen on the go
CORRECT!
Next question
touchRESPIRATORY touchRESPIRATORY
Pulmonary Embolism, Pulmonary Hypertension

Luis Jara Palomares, ERS 2019 – Environmental Factors in Pulmonary Embolism and PAH

Share this Video
Copy Link
Published Online: Oct 15th 2019

Luis Jara-Palomares, from Seville, Spain, joins us at ERS 2019 in Madrid, to discuss the main findings from his study into the significance of environmental factors in pulmonary embolism and pulmonary arterial hypertension.

Questions
1. What are the major causes of pulmonary embolism and pulmonary arterial hypertension? (0:06)
2. What is known about the impact of air pollution on pulmonary embolism and pulmonary arterial hypertension? (0:53)
3. What other environmental risk factors for pulmonary embolism/pulmonary arterial hypertension have been identified? (1:50)
4. What are the possible mechanisms underlying these environmental risk factors? (2:37)
5. What are the key take-home messages of your presentation? (3:14)

Speaker disclosures: Luis Jara-Palomares has nothing to disclose in relation to this video interview.

touchRESPIRATORY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.

Filmed at the European Respiratory Society (ERS) International Congress 2019, Madrid, Spain.

Related Videos In Pulmonary Hypertension
Interstitial Lung Disease, Pulmonary Hypertension
Developed by Touch
Jean Elwing, CHEST 2022: Inhaled treprostinil for pulmonary hypertension due to interstitial lung disease – the INCREASE OLE study
Watch Time: 6 mins

INCREASE OLE was the open-label extension of the INCREASE study (NCT02630316), which investigated the safety and efficacy of inhaled treprostinil in patients with pulmonary hypertension due to interstitial lung disease. We caught up with Prof. Jean Elwing (UC Health, Cincinnati, OH, USA) to discuss the methodology, inclusion criteria, and safety and tolerability findings from the […]

Pulmonary Hypertension
Developed by Touch
Marc Simon, CHEST 2022: Clinical benefits with a higher dose of LIQ861 in pulmonary arterial hypertension – analysis of the LTI-301 clinical trial
Watch Time: 5 mins

INSPIRE (LTI-301 clinical trial) was a phase 3 study investigating the long-term safety and tolerability of LIQ861 in patients with pulmonary arterial hypertension (NCT03399604). touchRESPIRATORY were delighted to talk with Dr. Marc Simon (UCSF Health, San Francisco, CA, USA) around the aims, design and eligibility criteria of the LTI-301 clinical trial and the findings from […]

Pulmonary Hypertension
Developed by Touch
Marc Simon, CHEST 2022: LIQ861 for the treatment of pulmonary arterial hypertension
Watch Time: 2 mins

LIQ861 is an investigational, inhaled dry powder formulation of treprostinil delivered through a device, which currently has tentative approval from the FDA for the treatment of pulmonary arterial hypertension (PAH). touchRESPIRATORY were delighted to talk with Dr. Marc Simon (UCSF Health, San Francisco, CA, USA) about LIQ861 and its potential advantages over conventional formulations of […]

Trending In Pulmonary Hypertension:

Jean Elwing, CHEST 2022: Inhaled treprostinil for pulmonary hypertension due to interstitial lung disease – the INCREASE OLE study
Interstitial Lung Disease, Pulmonary Hypertension
    • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72